NCT06654336 2026-03-13
RATIONAL
Ontario Clinical Oncology Group (OCOG)
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06798558 2026-02-19
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Hackensack Meridian Health
Phase 2 Recruiting
NCT06470750 2026-01-20
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
Mayo Clinic
Recruiting
NCT05050084 2026-01-14
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Recruiting
NCT04175431 2025-12-18
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
Phase 2 Recruiting
NCT05998278 2025-12-18
Personalized Optimization of Systematic Prostate Biopsy
Fujian Medical University Union Hospital
Phase NA Recruiting
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT05665738 2025-04-29
Two-fraction HDR Monotherapy for Localized Prostate Cancer
University of California, San Francisco
Phase NA Recruiting
NCT06044857 2025-03-12
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT06736054 2024-12-16
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Hoag Memorial Hospital Presbyterian
Phase 1 Recruiting